World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
60
Citations
12782
World Ranking
11960
National Ranking
5133

Overview

Gary L. Schieven is affiliated with Genesis Biotechnology Group in the United States. Their research primarily focuses on immunology and microbiology, with a notable number of publications in related fields such as medicine. The scientist's work spans several subfields, including immunology, infectious diseases, molecular biology, oncology, and emergency medical services.

The main topics covered in their research include:

  • Immune Response and Inflammation
  • Interferon and Immune Responses
  • Immune Cells in Cancer
  • Pediatric Health and Respiratory Diseases
  • Asthma and Respiratory Diseases
  • Viral Infections and Vectors
  • Viral Infections and Outbreaks Research

Gary L. Schieven has contributed to several research articles, including:

  • Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9), 2020, ACS Medicinal Chemistry Letters
  • Discovery of Non-Nucleotide Small-Molecule STING Agonists via Chemotype Hybridization, 2022, Journal of Medicinal Chemistry
  • Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8), 2022, ACS Medicinal Chemistry Letters
  • STING Agonist VB-85247 Induces Durable Antitumor Immune Responses by Intravesical Administration in a Non-Muscle-Invasive Bladder Cancer, 2024, Cancer Research
  • Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology, 2024, ACS Medicinal Chemistry Letters

The most common publication venues for their work include:

  • ACS Medicinal Chemistry Letters
  • Cancer Research
  • Journal of Medicinal Chemistry
  • Annals of the Rheumatic Diseases

Gary L. Schieven has collaborated frequently with several researchers, including:

  • David Critton
  • Shailesh Dudhgaonkar
  • Shana Posy
  • Sanjeev Gangwar
  • Gregory D. Vite

Best Publications

  • Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

    Louis J. Lombardo;Francis Y. Lee;Ping Chen;Derek Norris

  • Positive selection for loss of tetracycline resistance.

    B R Bochner;H C Huang;G L Schieven;B N Ames

  • 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.

    Jagabandhu Das;Ping Chen;Derek Norris;Ramesh Padmanabha

  • Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction.

    Carl H. June;Mary C. Fletcher;Jeffrey A. Ledbetter;Gary L. Schieven

  • The biology of p38 kinase: a central role in inflammation.

    Gary L. Schieven

  • Reactive oxygen intermediates activate NF-kappa B in a tyrosine kinase- dependent mechanism and in combination with vanadate activate the p56lck and p59fyn tyrosine kinases in human lymphocytes

    Gary L. Schieven;Jean M. Kirihara;Dorothea E. Myers;Jeffrey A. Ledbetter

  • Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.

    Andrew E. Schade;Gary L. Schieven;Robert Townsend;Anna M. Jankowska

  • Cross-linking of Fc gamma receptor I (Fc gamma RI) and receptor II (Fc gamma RII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase.

    P A Kiener;B M Rankin;A L Burkhardt;G L Schieven

  • CD28 ligation in T-cell activation: evidence for two signal transduction pathways.

    Jeffrey A. Ledbetter;John B. Imboden;Gary L. Schieven;Laura S. Grosmaire

  • The role of class II molecules in human B cell activation. Association with phosphatidyl inositol turnover, protein tyrosine phosphorylation, and proliferation.

    Peter J L Lane;Fiona M. McConnell;Gary L. Schieven;Edward A. Clark

  • ZAP-70 tyrosine kinase, CD45, and T cell receptor involvement in UV- and H2O2-induced T cell signal transduction.

    Gary L. Schieven;Robert S. Mittler;Steven G. Nadler;Jean M. Kirihara

  • The role of tyrosine phosphorylation in signal transduction through surface Ig in human B cells. Inhibition of tyrosine phosphorylation prevents intracellular calcium release.

    Peter J L Lane;Jeffrey A. Ledbetter;Fiona M. Mcconnell;Kevin Draves

  • p72syk tyrosine kinase is activated by oxidizing conditions that induce lymphocyte tyrosine phosphorylation and Ca2+ signals.

    Gary L. Schieven;Jean M. Kirihara;Debra L. Burg;Robert L. Geahlen

  • Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc gamma-IIA receptor.

    F. Yanaga;A. Poole;J. Asselin;R. Blake

  • Cloning and expression of the tumor-associated antigen L6.

    John S. Marken;Gary L. Schieven;Ingegerd Hellstrom;Karl Erik Hellstrom

  • Role of Oxidative Stress in the Action of Vanadium Phosphotyrosine Phosphatase Inhibitors REDOX INDEPENDENT ACTIVATION OF NF-κB

    Cecile M. Krejsa;Steven G. Nadler;James M. Esselstyn;Terrance J. Kavanagh

  • Collagen stimulates tyrosine phosphorylation of phospholipase C‐γ2 but not phospholipase C‐γ1 in human platelets

    Robert A. Blake;Gary L. Schieven;Steve P. Watson

  • Tyrosine phosphorylation is a mandatory proximal step in radiation-induced activation of the protein kinase C signaling pathway in human B-lymphocyte precursors

    Fatih M. Uckun;Gary L. Schieven;Lisa M. Tuel-Ahlgren;Ilker Dibirdik

  • Interaction of the Cytoplasmic Tail of CTLA-4 (CD152) with a Clathrin-Associated Protein Is Negatively Regulated by Tyrosine Phosphorylation

    Jeffrey D. Bradshaw;Pin Lu;Gina Leytze;Julie Rodgers

  • Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases by the Pan-B-cell receptor CD40/Bp50 at discrete developmental stages of human B-cell ontogeny.

    Fatih M. Uckun;Gary L. Schieven;Ilker Dibirdik;Mridula Chandan-Langlie

Frequent Co-Authors

Jeffrey A. Ledbetter
Jeffrey A. Ledbetter University of Washington
Alejandro Aruffo
Alejandro Aruffo Syngenta (United States)
Marilyn Parsons
Marilyn Parsons University of Washington
Edward A. Clark
Edward A. Clark University of Washington
Joseph B. Bolen
Joseph B. Bolen Takeda (Japan)
Peter S. Linsley
Peter S. Linsley Benaroya Research Institute
Paul J. Martin
Paul J. Martin Fred Hutchinson Cancer Research Center
Ingegerd Hellström
Ingegerd Hellström University of Washington
Karl Erik Hellström
Karl Erik Hellström University of Washington
Steve P. Watson
Steve P. Watson University of Birmingham

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Gary L. Schieven

Trending Scientists